Transmission-blocking vaccines

Chemical Immunology

Volumn 80, Issue , 2002, Pages 287-307

  Kaslow, David C ^a  

^a VICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMODIUM VIVAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPOROZOITE;

EID: 0036090383     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058850     Document Type: Review

References (56)

1. Transmission-blocking vaccines
2. Note sur un nouveau parasite trouve dans le sang du plusieurs malades atteints de fièvre palustre
3. Report on the cultivation of Proteosoma, Labbe, in grey mosquitoes
4. On the haematozoan infections in birds
5. Changes in infectiousness of malarial gametocytes. II. Analysis of the possible causative factors
6. Successful immunization against the sexual stages of Plasmodium gallinaceum
7. Malaria transmission blocked by immunisation with gametes of the malaria parasite
8. Target antigens of transmission-blocking immunity on gametes of Plasmodium falciparum
9. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito
10. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains
11. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals
12. Erythropoiesis and molecular mechanisms for sexual determination in malaria parasites
13. Commitment to sexual differentiation in the human malaria parasite, Plasmodium falciparum
14. Virulence and transmission success of the malarial parasite Plasmodium falciparum
15. Malaria transmission and naturally acquired immunity to PfEMP-1
16. CD36-dependent adhesion and knob expression of the transmission stages of Plasmodium falciparum is stage specific
17. A model for sequestration of the transmission stages of Plasmodium falciparum: Adhesion of gametocyte-infected erythrocytes to human bone marrow cells
18. Gametocytes
19. Identification of xanthurenic acid as the putative inducer of malaria development in the mosquito
20. Adherence of erythrocytes during exflagellation of Plasmodium falciparum microgametes is dependent on erythrocyte surface sialic acid and glycophorins
21. The peritrophic membrane as a barrier: Its penetration by Plasmodium gallinaceum and the effect of a monoclonal antibody to ookinetes
22. Inhibition of malaria parasite development in mosquitoes by anti-mosquito-midgut antibodies
23. Effect of anti-mosquito antibodies on the infectivity of the rodent malaria parasite Plasmodium berghei to Anopheles farauti
24. Cloning and expression of the gene for Plasmodium falciparum transmission-blocking target antigen, Pfs230
25. Characterization of Plasmodium falciparum sexual stage antigens and their biosynthesis in synchronised gametocyte cultures
26. Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum
27. Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies
28. Stage-specific processing of Pfs230, a Plasmodium falciparum transmission-blocking vaccine candidate
29. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes
30. Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230
31. Transmission blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype dependent
32. Phagocytosis does not play a major role in naturally acquired transmission-blocking immunity to Plasmodium falciparum malaria
33. Strain polymorphism of Plasmodium falciparum transmission-blocking target antigen Pfs230
34. Minimal variation in the transmission-blocking vaccine candidate Pfs48/45 of the human malaria parasite Plasmodium falciparum
35. Effects of transmission-blocking monoclonal antibodies on different isolates of Plasmodium falciparum
36. Conserved and variant epitopes of target antigens of transmission-blocking antibodies among isolates of Plasmodium falciparum from Malaysia
37. Boosting of transmission-blocking immunity during natural Plasmodium vivax infections in humans depends upon frequent reinfection
38. Plasmodium knowlesi: Persistence of transmission blocking immunity in monkeys immunized with gamete antigens
39. Development of a single injection transmission-blocking malaria vaccine using biodegradable microspheres
40. Chitinases of the avian malaria parasite Plasmodium gallinaceum, a class of enzymes necessary for parasite invasion of the mosquito midgut
41. Transmission-blocking activity of a chitinase inhibitor and activation of malarial parasitechitinase by mosquito protease
42. Antibody-mediated inhibition of Aedes aegypti midgut trypsins blocks sporogonic development of Plasmodium gallinaceum
43. Different effects of modulation of mosquito (Diptera:Culicidae) trypsin activity on the infectivity of two human malaria (Hemosporidia:Plasmodidae) parasites
44. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum
45. Pgs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies,
46. Mapping of two overlapping linear epitopes in Pfg27 recognized by Plasmodium falciparum transmission-blocking monoclonal antibodies
47. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines
48. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes
49. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies
50. Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus
51. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose
52. Plasmodium falciparum: Immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate
53. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid
54. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes
55. Gametocyte infectivity by direct mosquito feeds in an area of seasonal malaria transmission: Implications for Bancoumana, Mali as a transmission-blocking vaccine site